Insulin Sensitivity in Women with Polycystic Ovary Syndrome
Jana VrbÍková,
David Cibula,
Kateina Dvoáková,
Soa Stanická,
Gustav indelka1,
Martin Hill,
Michael Fanta,
Karel Vondra and
Jan krha
Institute of Endocrinology (J.V., K.D., S.S., M.H., K.V.), and Departments of Obstetrics and Gynecology (D.C., M.F.) and Internal Medicine (G.., J..), Charles University in Prague, Prague, 116 94 Czech Republic
Address all correspondence and requests for reprints to: Jana Vrbíková, M.D., Institute of Endocrinology, Národní 8, Prague 1, 116 94 Czech Republic. E-mail: jvrbikova{at}endo.cz.
The aim of our study was to compare insulin sensitivity in leanand obese European polycystic ovary syndrome (PCOS) women withlean healthy women. We performed the euglycemic hyperinsulinemicclamp in 83 women with PCOS [53 lean with body mass index (BMI)of 21.5 ± 1.8 kg/m2 and 30 obese with BMI of 29.6 ±3.7 kg/m2] and in 15 healthy women with BMI of 21.6 ±1.8 kg/m2 to determine glucose disposal (M) and the insulinsensitivity index (ISI). Statistical evaluation was done usingKruskal-Wallis ANOVA followed by Kruskal-Wallis multiple-comparisonz-value test. The basal blood glucose was significantly higherin lean and obese PCOS women than in controls (P < 0.02).Fasting insulin was significantly higher in both lean and obesePCOS women than in controls (P < 0.000001). Obese PCOS womenwere more insulin resistant than controls (P < 0.02 for Mand P < 0.0008 for ISI); lean PCOS women did not differ fromcontrols in M or ISI. Posthepatic insulin delivery was significantlyhigher in both lean and obese PCOS women compared with controls(P < 0.000008). We conclude that lean PCOS women are notmore insulin resistant than healthy controls. Insulin hypersecretion,on the other hand, is present even in lean PCOS women.
This work was supported by Grants NB/6696-3 and NH/6558-3 fromthe Internal Grant Agency of the Czech Ministry of Health.
J.V. and D.C. contributed equally to the study.
Abbreviations: A, Androstenedione; BMI, body mass index; CV,coefficient of variance; DHEA, dehydroepiandrosterone; DHEA-S,dehydroepiandrosterone sulfate; ISI, insulin sensitivity index;M, glucose disposal rate; MCRI, posthepatic clearance rate ofplasma insulin; PCOS, polycystic ovary syndrome; PHD, posthepaticinsulin delivery; T, testosterone.
1 G.. died tragically in 2001.
This article has been cited by other articles:
N. Sattar Review: PCOS, insulin resistance and long-term risks for diabetes and vascular disease
The British Journal of Diabetes & Vascular Disease,
January 1, 2009;
9(1):
15 - 18.
[Abstract][PDF]
I. J. G. Ketel, C. D. A. Stehouwer, E. H. Serne, T. J. M. Korsen, P. G. A. Hompes, Y. M. Smulders, R. T. de Jongh, R. Homburg, and C. B. Lambalk Obese But Not Normal-Weight Women with Polycystic Ovary Syndrome Are Characterized by Metabolic and Microvascular Insulin Resistance
J. Clin. Endocrinol. Metab.,
September 1, 2008;
93(9):
3365 - 3372.
[Abstract][Full Text][PDF]
P. F. Svendsen, L. Nilas, K. Norgaard, J.-E. B. Jensen, and S. Madsbad Obesity, body composition and metabolic disturbances in polycystic ovary syndrome
Hum. Reprod.,
September 1, 2008;
23(9):
2113 - 2121.
[Abstract][Full Text][PDF]
J. Vrbikova, M. Hill, B. Bendlova, T. Grimmichova, K. Dvorakova, K. Vondra, and G. Pacini Incretin levels in polycystic ovary syndrome
Eur. J. Endocrinol.,
August 1, 2008;
159(2):
121 - 127.
[Abstract][Full Text][PDF]
B. Trolle, A. Flyvbjerg, U. Kesmodel, and F.F. Lauszus Efficacy of metformin in obese and non-obese women with polycystic ovary syndrome: a randomized, double-blinded, placebo-controlled cross-over trial
Hum. Reprod.,
November 1, 2007;
22(11):
2967 - 2973.
[Abstract][Full Text][PDF]
S. Hahn, U. H Frey, W. Siffert, S. Tan, K. Mann, and O. E Janssen The CC genotype of the GNAS T393C polymorphism is associated with obesity and insulin resistance in women with polycystic ovary syndrome.
Eur. J. Endocrinol.,
November 1, 2006;
155(5):
763 - 770.
[Abstract][Full Text][PDF]
Z. T. Bloomgarden Third Annual World Congress on the Insulin Resistance Syndrome: Associated conditions.
Diabetes Care,
September 1, 2006;
29(9):
2165 - 2174.
[Full Text][PDF]
L. Poretsky Polycystic Ovary Syndrome--Increased or Preserved Ovarian Sensitivity to Insulin?
J. Clin. Endocrinol. Metab.,
August 1, 2006;
91(8):
2859 - 2860.
[Full Text][PDF]
T. Tang, J. Glanville, C. J. Hayden, D. White, J. H. Barth, and A. H. Balen Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study
Hum. Reprod.,
January 1, 2006;
21(1):
80 - 89.
[Abstract][Full Text][PDF]
T. J Wilkin and L. D Voss Metabolic syndrome: maladaptation to a modern world
J R Soc Med,
November 1, 2004;
97(11):
511 - 520.
[Full Text][PDF]